Q&A: Once-Daily Hypertension Polypill Could Lower Recurrent Stroke, Cardiovascular Events

Intracerebral hemorrhage accounts for roughly 3 million new cases annually worldwide, and the prognosis for survivors remains sobering. Approximately 25% of patients who survive an initial intracerebral hemorrhage will later die from recurrent stroke or cardiovascular disease. Despite this risk, achieving sustained blood pressure control in this population has proven difficult, with many patients receiving inadequate antihypertensive therapy due to the complexity of multi-drug regimens.

The TRIDENT trial, a multinational, double-blind, randomized, placebo-controlled study led by The George Institute for Global Health, addressed that challenge directly. Enrolling 1670 patients with a history of intracerebral hemorrhage and baseline systolic blood pressure of 130 to 160 mmHg, the trial evaluated GMRx2, a once-daily single pill combining telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg, against placebo added to standard care. At a median follow-up of 2.5 years, recurrent stroke occurred in 4.6% of patients in the GMRx2 group versus 7.4% in the placebo group (HR, 0.61; 95% CI, 0.41 to 0.92; P = 0.02), and the incidence of major cardiovascular events was also lower with GMRx2 (6.6% vs. 9.8%; P = 0.04), according to results published in The New England Journal of Medicine.

"Lowering blood pressure is the only proven method to prevent another stroke, yet achieving good blood pressure control is a real challenge," said Craig Anderson, PhD, principal investigator and senior professorial fellow at The George Institute for Global Health. "Our study showed that GMRx2, a once-daily triple combination pill, cut the risk of another stroke by 39%."

In the following interview, Anderson discusses the TRIDENT trial design, its clinical implications, and the potential for GMRx2 to address blood pressure management gaps across diverse patient populations globally.

How a Low‑Dose Triple Antihypertensive Pill Improves Outcomes After Intracerebral Hemorrhage, With Craig Anderson, PhD

Q: Could you provide a brief overview of the TRIDENT study and how we got to where we are?

A: The TRIDENT study is a 10-year project to determine the benefits of long-term blood pressure (BP) lowering with a novel, low-dose triple combination antihypertensive medication to prevent stroke in patients with a history of ICH. The results were very positive: this approach to controlling BP prevents future stroke events.

Q: The study showed a 39% reduction in recurrent stroke and a 33% reduction in major adverse cardiovascular events. How clinically meaningful are these findings in day-to-day stroke and cardiology practice?

Anderson: They are very meaningful. That's a big treatment benefit that is not seen very often in long term prevention of cardiovascular diseases. The relative benefit translated into a significant absolute benefit, that is number needed to treat, which is impressive. The cardiovascular prevention was driven primarily by the prevention of recurrent ICH. If a patient has had a bleed in the brain, they are at high risk of future bleeds in the brain—as well as ischemic events in the brain and heart—but the most worrying is recurrent bleeding.

Q: The mean systolic blood pressure difference between groups was about 9mmHg. How should clinicians interpret that relationship between what seems like a modest BP reduction and such a substantial reduction in recurrent stroke risk?

Anderson: One of the problems that we've had in BP control for secondary prevention after stroke is just achieving the targets. Whether that is less than 140 mmHg or more stringently less than 130 mmHg, it is very challenging to do in clinical practice. Most patients will require multiple medications, which can cause problems with medication adherence, and it is tiring for clinicians to review patients regularly to do that. The TRIDENT trial shows that achieving BP less than 130 mmHg because our active group had achieved that, and that's now, for the first time, in a direct patient group, randomized controlled trial, that we've shown the benefits of that, and we've also shown that the triple pill approach can do that very effectively compared to standard treatment. So a 9 to 10 mmHg reduction is the equivalent of two extra pills and at full dose, which is very meaningful.

Q: ICH disproportionately affects patients in low-and middle-income countries (LMICs). Could a fixed dose combination strategy meaningfully narrow global disparities in stroke outcomes? Or are there still major barriers to implementation beyond just prescription?

Anderson: There is no doubt that ICH follows populations where there is untreated hypertension and other risk factors, such as high intake of salt and environmental temperatures (ie, when the temperature drops down to cold levels, that pushes the blood pressure). There's a lot of other factors that are relevant. The other issue in LMICs is health literacy and cost barriers. A triple, low dose combination pill is potentially an effective, simple, and relatively low cost strategy that could go a long way to controlling hypertension levels broadly across the population and those who are at high risk, such as previous history of stroke. But it's one strategy, and there's a lot of other things that we need to overcome. The big problem all around the world is adherence. Forgetting to take your pills, not appreciating the importance of medication adherence, and I think we all need to work on better systems of care that engage our patients to help them understand the importance of ongoing treatment for hypertension, which for the most part, is asymptomatic. You cannot really feel high levels in your body, and to appreciate the importance of taking the treatment long term is really a goal of our health practitioners.

Q: GMRx2 combines telmisartan, amlodipine, and indapamide at low doses. What is your view on the pharmacologic rationale for this combination, and do you think the benefit is mostly about the drugs themselves or the simplification of adherence?

Anderson: No. There is a good scientific rationale for this combination, and that is that you get synergistic therapeutic effects without the side effects. Most of the benefits of an antihypertensive treatment happen when you achieve half of a standard dose. Going up to a full standard dose does not achieve much additional gain, but you get more side effects. Using the combination of pills through different pharmacotherapeutic mechanisms in the body can achieve a bigger blast in terms of controlling BP without all of the side effects. Moreover, putting them together into a single pill means patients only have to take one pill as opposed to multiple pills. One of the key things that is under appreciated in clinical practice is that if you have had a stroke, you need to have very good BP control, but that is hard to achieve just with a single standard antihypertensive medication. Patients will need 2, 3, and sometimes 4 pills to achieve good control.

Q: In real-world practice, clinicians often inherit patients who are already taking various antihypertensives. How would you approach transitioning someone from an individualized regimen to a fixed dose, triple pill like GMRx2?

Anderson: There area couple of issues related to that question. The first is that it is always difficult to change treatments that a patient has been on for a long time and is familiar to them. That does require some discussion, engagement, and understanding for the rationale of that. The second is that there are certain medications that cannot be combined. For example, we don't like to combine an ACE inhibitor with an ARB because it can cause more complete blockage of the VRENIN angiotensin system and that may have adverse therapeutic effects on kidney function. And we obviously don't like to combine pills that increase the total dose above recommended the therapeutic levels, so there does need to be an understanding about moving over or adding additional treatments. That was a particular requirement going into our TRIDENT study. Participants had to be on an ARB, an ACE, an ARB, a calcium channel blocker, a diuretic at low-to-standard doses so they could go into our trial without compromising the therapy. The important thing about TRIDENT was the additional benefit that was achieved by most of the participants already having treatment. Most individuals were on multiple drugs and were within clinicians understanding of good control. Even with that, the addition of GMRx2 to achieve this amazing extra benefit was an extra boost to them. So, it's a simple transition, but it does require a little bit of consideration and engagement with the patient to understand the rationale for doing that, but GMRx2 is better tolerated and is a much simpler regime and should go smoothly with most patients.

Reference: George Institute for Global Health. Low-dose triple-pill cut risk of recurrent stroke by about 40%, global trial shows. News release. April 22, 2026. Accessed April 22, 2026. https://www.eurekalert.org/news-releases/1124713